STOCK TITAN

Atara Biotherape - ATRA STOCK NEWS

Welcome to our dedicated page for Atara Biotherape news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherape stock.

Atara Biotherapeutics (NASDAQ: ATRA) is a leading innovator in cellular immunotherapy, developing transformative treatments for cancer and autoimmune diseases. This news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory milestones, and strategic partnerships.

Access timely updates on T-cell therapy advancements, including CAR T platform developments and collaboration progress with Memorial Sloan Kettering Cancer Center. Our curated collection features press releases about product candidates in oncology and autoimmune research, financial disclosures, and manufacturing updates.

Key content includes analysis of Phase 1-3 trial outcomes, FDA communications regarding allogeneic therapies, and licensing agreements supporting ATRA's pipeline development. Bookmark this page for direct access to primary source materials and objective reporting on the company's progress in addressing unmet medical needs through innovative immunotherapies.

Rhea-AI Summary
Atara Biotherapeutics grants 116,550 restricted stock units to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.41%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.94%
Tags
conferences
-
Rhea-AI Summary
Atara Biotherapeutics announces updated effectiveness and safety data for tabelecleucel in treating EBV+ PTLD patients. Objective response rate (ORR) of 67% observed in 24 patients. One-year survival rate of 91% for responders compared to 34% for non-responders. Real-world results affirm the favorable risk-benefit profile of tabelecleucel.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.85%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
none
Rhea-AI Summary

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, has announced that it will release its first quarter 2023 financial results after market close on Monday, May 8, 2023. The company specializes in developing transformative therapies for patients with cancer and autoimmune diseases, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.19%
Tags
-
Rhea-AI Summary

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) announced the grant of 93,950 restricted stock units to three newly hired employees, approved by the Compensation Committee of Atara’s Board of Directors. This grant, effective from April 3, 2023, is part of Atara's 2018 Inducement Plan and serves as an employment inducement under Nasdaq Listing Rule 5635(c)(4). The stock units will vest over four years, with 25% vesting after one year and the remainder in equal quarterly installments. Atara specializes in T-cell immunotherapy, developing therapies for cancer and autoimmune diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
none
-
Rhea-AI Summary

Atara Biotherapeutics (NASDAQ: ATRA) has announced the grant of 62,350 restricted stock units to six new employees as an inducement to join the company. This award, approved by Atara's Compensation Committee, was granted under the 2018 Inducement Plan and will vest over four years, with 25% vesting on the first anniversary and the remaining vesting in 12 quarterly installments. Atara focuses on T-cell immunotherapy, developing treatments for cancer and autoimmune diseases using its EBV T-cell platform. The company aims to deliver off-the-shelf therapies to patients with significant needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.99%
Tags
none
Rhea-AI Summary

Atara Biotherapeutics (NASDAQ: ATRA) announced its CEO, Pascal Touchon, will participate in a cell therapy panel at the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 11:10 a.m. PST. The event will showcase the company's allogeneic Epstein-Barr virus (EBV) T-cell platform, aimed at developing therapies for cancer and autoimmune diseases. A live webcast will be available on Atara's website, with an archived replay accessible for 30 days post-event. Atara is at the forefront of T-cell immunotherapy, offering innovative treatments for serious diseases, including their lead program, tab-cel, which has received marketing authorization in Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.44%
Tags
conferences
Atara Biotherape

Nasdaq:ATRA

ATRA Rankings

ATRA Stock Data

36.15M
4.52M
21.98%
50.5%
12.2%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
THOUSAND OAKS